Chronic myeloid leukemia with expression of ALL-type BCR/ABL transcript: a case-report and review of the literature.
CML with exclusive expression of ALL-type bcr/abl has only been rarely described. In some cases, the presence of this fusion gene has been associated to a differentiated subtype of CML that share some features with CMML, while in another case this molecular hallmark has been associated to a bad prognosis of the disease with a blast phase as clinical presentation or an early transformation to blast phase. We report a case of a 30-year-old woman who was diagnosed of CML in chronic phase in May 1989. She received treatment first with busulfan, achieving hematological remission and afterwards with interferon and Hydroxiurea. In February 1998, she was admitted at our hospital for an ABSCT. Then, molecular studies were performed. Multiplex PCR revealed the presence of a 481 bp product identified as the ela2 bcr/abl transcript and confirmed by sequencing. After 9 years from diagnosis, the patient remains in hematological remission and in good clinical condition.
Solves
P
P
Department of Hematology, Hospital Universitari La Fe, Valencia, Spain.
Bolufer
P
P
López
J A
JA
Barragán
E
E
Bellod
L
L
Ferrer
S
S
Rosell
A
A
Lerma
E
E
Cervera
J
J
de la Rubia
J
J
Sanz
G F
GF
Sanz Alonso
M A
MA
D000328:Adult; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics*; D012333:RNA, Messenger / Q000096:biosynthesis*
D012333:RNA, Messenger; D016044:Fusion Proteins, bcr-abl